7月7日 - ** 药物开发商科景生物COGT.O股价盘前上涨19.4%至9.05美元
** 该公司称其药物贝珠司替尼（bezuclastinib）对肥大细胞增多症（一种血液疾病）患者症状的减轻具有统计学意义
** 肥大细胞增多症是一种人体制造过多一种名为肥大细胞的白细胞的疾病，这种白细胞会在骨髓、皮肤或器官等部位堆积。
** COGT公司预计将在2025年底前提交该疗法的上市申请
** 截至上次收盘，股价累计下跌2.8
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.